Presentation on theme: "Biophan Technologies, Inc. Biophans Patented Innovations Improve Medical Devices 2005 Money Show Michael Weiner, CEO."— Presentation transcript:
Biophan Technologies, Inc. Biophans Patented Innovations Improve Medical Devices 2005 Money Show Michael Weiner, CEO
Biophan Technologies, Inc.(OTCBB: BIPH) MEDICAL INNOVATION The United States and most modern countries place a very high value on medical innovation Once approved in the market, a medical innovation can generate significant wealth for the inventors and for the shareholders of the company(s) bringing the innovation to market Over the past fifty years, medical innovations have changed the quality of life immensely, and made many large, and small, fortunes
Biophan Technologies, Inc.(OTCBB: BIPH) PATENTS AND MONEY U.S. Patents are one of the most potentially valuable financial instruments in the world Once issued, they provide the exclusive right to make, use, or sell, the invention within the United States of America The claims are where the true value lies One claim can be worth as much as $1 billion (Polaroid vs. Kodak)
Biophan Technologies, Inc.(OTCBB: BIPH) Enhancements Once a product is on the market, another series of innovations and enhancements to the core device can create significant additional wealth Some examples: demand pacing enhancement over pacemakers The implantable defibrillator enhancement Communicating pacemakers Implantable insulin pumps Hundreds more, worth BILLION$
Biophan Technologies, Inc.(OTCBB: BIPH) BIOPHANs BUSINESS Founded with pacemaker inventor Wilson Greatbatch, to make pacemakers safe for use with MRI Expanded to include $12 billion worth of medical devices that ship with one problem, or another Problems had not been solved by the medical device manufacturers Finding, and patenting, a solution, would help patients, and help manufacturers offer a better device That was the founding idea behind Biophan Without a strong U.S. Patent system, there would be little incentive to invest money on solutions like this
Biophan Technologies, Inc.(OTCBB: BIPH) INNOVATIONS IN INNOVATION Biophan invests shareholder dollars… To discover, patent, and implement Valuable enhancements to multi-billion dollar device markets Where the resulting innovation can make a major shift in marketshare, among major industry players, in major industries Biophan holds 36 issued US patents, and has 72 more pending; plus many international patents
Biophan Technologies, Inc.(OTCBB: BIPH) Management Stu MacDonald, VP R&D – formerly VP R&D at J&J division, with a 400 person organization Jeff Helfer, VP Engineering – formerly Dir. Of Engineering at the same J&J division John Lanzafame, President, Nanolution Division – former President STS Biopolymers, acquired by Angiotech (ANPI) Robert Wood, VP Finance, Treasurer, Secretary, and CFO – CPA in public and private firms Michael Friebe, Ph.D., MRI Scientist & Entrepreneur Andreas Melzer, MD, renowned medical innovator
Biophan Technologies, Inc.(OTCBB: BIPH) Biophans Mission Enable over $12 billion worth of medical devices shipping annually safe for use with MRI, and imageable. Many are not: Guidewires, catheters, endoscopes, biopsy needles Pacemakers, defibrillators, neurostimulators, drug pumps (safety issues, also imaging issues), pain control devices Stents, embolism clips, aneurysm clips, artificial hips, knees, most other orthopedics Bring other innovations for competitive advantage to biomedical device and pharmaceutical companies.
Biophan Technologies, Inc.(OTCBB: BIPH) Biophans Solutions MRI Safety: (many products contraindicated) RF filter from Johns Hopkins (heating) Anti-Antenna lead design (heating & induced voltages) MRI Safe non-magnetic motor Nanomagnetic particle technologies Minimize image artifacts Makes catheters, guidewires, stents, etc visible under MRI Contrast agents Drug Delivery
Biophan Technologies, Inc.(OTCBB: BIPH) PROTECTED, PROTECTED! Technologies covered by 114 U.S. Patents 36 ISSUED 72 pending or allowed Owned by Biophan or licensed exclusively to Biophan for the medical market Plus many International patents
MRI Device Imaging SE coronal image of 3 aluminum wires (1/32). Wire (3) is uncoated. 123 Biophans thin-film nanomagnetic particle coating technology provides a controllable, magnetic signal capable of creating an image of the coated device. #3 is uncoated.
Biophan Technologies, Inc.(OTCBB: BIPH) Making Stents Imageable Seeing blockage of stents has required an invasive procedure Stents imageable under MRI would be competitively advantaged Nanoset has a nanomagnetic particle, thin film coating AMRIS, now Biophan-Europe, has a retrofit solution Both solutions are PATENTED!
Biophan Technologies, Inc.(OTCBB: BIPH) 1.5 Tesla MRI Artifacts of Current Stents Expanded Stents Original size Crimped Stents Cobalt 316L stainless steel With existing stent technology, no useful images can be obtained from within common stents using MRI.
Imaging of In-Stent Blood Clots Using Biophan Resonator Technology 1 Tesla Philips NT, head coil, TR=300ms, TE=6ms, FA=40°, transversal Cross Sectional Schematic of Stent with blood clot Video Biophans technology enables imaging of the blood clot within the stent Resonant StentBlood Clot
Biophan Technologies, Inc.(OTCBB: BIPH) Implications Impact the $5+ billion stent market Help manufacturers make pacemakers, defibrillators, and neurostimulators safe, and imageable – competitive advantage to our licensees Make guidewires, catheters, endoscopes, and biopsy needles safe and image compatible Opens the field of interventional medicine under MRI (currently only X-Ray/Fluoroscopy)
Biophan Technologies, Inc.(OTCBB: BIPH) Biothermal Battery Goal: To provide a long-lived electrical power system for implanted medical devices Powered by body heat differential. Batteries are a $500 million market, sell for $100 to $225 each in the pacemaker, defibrillator and drug pump markets Sold to same customers who need MRI safety Nanomaterials brings this capability within striking distance. We hold issued and pending patents
Biophan Technologies, Inc.(OTCBB: BIPH) Agreement with NASA Announced on August 17 th a deal with NASA Ames Research Center for Nanotechnology to jointly develop the biothermal battery NASA wants technology for their long duration manned MARS mission for biosensing and miniature therapeutic devices Biophan gets commercial rights to jointly developed and NASA developed technology Nanotechnology and materials science advances makes the biothermal battery possible
Non-Magnetic MRI-Safe and Imageable Greater efficiency Enables precision 20 nm movements Ideal for drug pumps, cryogenic applications, implantables Biophan holds worldwide medical distribution rights, + equity
Biophan Technologies, Inc.(OTCBB: BIPH) Substrate Polymer Coating Nanomagnetic layer Controlled Magnetic Field Drug bound to NMP carrier Controlled Magnetic Field A Controlled Magnetic Field B Particle type A Drug A Particle type B Drug B Surface Elution on Demand
Biophan Technologies, Inc.(OTCBB: BIPH) Reloading Drug Eluting Coatings Substrate Polymer Coating Concentration Gradient Controlled Magnetic Field Drug Molecules Drug bound to NMP carrier Nanomagnetic layer
Biophan Technologies, Inc.(OTCBB: BIPH) Guided Drug Delivery Solid tumor Apply magnetic field to concentrate particles Modulate field to release drug from particles Inject NMPs IV, NMP will circulate through the blood stream Other options for targeting: 1 - Direct injection into tumor site 2 - Coating NMP with antibodies to target tumor
Biophan Technologies, Inc.(OTCBB: BIPH) Markets Medical devices (safe &/or image): $12 billion Battery: $500 million Contrast Agents: $800 million Drug Pumps: $1 billion Drug Delivery: $40 billion Once a deal is underway, patents and annuity streams can last a long time; We anticipate money on signing, in development; plus milestones, royalties, high margin components
Biophan Technologies, Inc.(OTCBB: BIPH) Business Model Offering our customers competitive advantage Through proprietary solutions that can gain marketshare for them FDA approval is pursued by the customer Marketing and distribution of the final device is their responsibility We sell high margin components and develop annuities for our shareholders
Biophan Technologies, Inc.(OTCBB: BIPH) Relationship With Boston Scientific Joint development agreement, originally entered into November, 2003 Recently moved to second and third phase, and has expanded to multiple products Reached agreement on term sheet, working on final contract phase
Biophan Technologies, Inc.(OTCBB: BIPH) Summary Financial Information Share Price ( ): $ Week High: $ Week Low: $0.46 Shares Outstanding: 74 million Float: 58 million Market Cap: $176 million Average Daily Volume: 1,218,772
Biophan Technologies, Inc.(OTCBB: BIPH) Biophan (OTC: BIPH) We dont make medical devices; We make them safe, and imageable, for MRI And other competitive advantages for our customers Four of our six technologies are based on nanotechnology